Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) and FOLFIRI…
Finding new cell markers to track the most aggressive breast cancer in blood
Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies. TNBC also is more likely to metastasize, or travel through…
Long-Term Study Suggests Walking Is Key to Managing Cancer-Related Fatigue #IG26 #ASCO
A new study found that regular physical activity, particularly walking, can significantly reduce cancer-related fatigue and improve quality of life in people with colorectal cancer, especially in the post-treatment setting.…
Antibody-drug conjugates emerge as potent anti-tumor agents for gynecological cancers
Gynecological cancers, primarily cervical, ovarian, and uterine cancer, continue to be a significant threat to women’s health worldwide. While surgery and chemotherapy are the current standard treatment, patients often face…
The diamonds that could find cancer
University of Warwick researchers have built a new diamond-based magnetic field sensor that could be used to better find tumours through tracing magnetic fluid injected in the body. A cancer…
A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a…